Spreadsheet: 0f89e410-d2c2-4976-96c9-1481d115c48e
Sheet: tab18

 |  | Estimated Vaccination Coverage*,† with Selected Vaccines Among Adolescents 13-17 Years of Age§ by Poverty Level¶ and Race/Ethnicity**  -- National Immunization Survey-Teen, United States, 2013
Vaccines |  | Total | White only,                        non-Hispanic | Black only,                         non-Hispanic | Hispanic | American Indian or [NAME] only, non-Hispanic | Asian only, non-Hispanic
 |  | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.)
≥2 MMR†† | US National | 91.8(±0.8) | 92.8(±0.8) | 91.1(±2.4) | 90.2(±2.3) | 93.5(±5.2) | 90.8(±6.0)
 | At or Above Poverty | 91.8(±0.9) | 92.7(±0.9) | 91.5(±2.7) | 89.5(±3.8) | 95.3(±4.0) | 89.5(±7.3)
 | Below Poverty | 91.7(±1.7) | 93.3(±2.1) | 90.6(±4.7) | 91.2(±2.6) | 92.4(±11.2) | 94.7(±6.7)
 | Unknown Poverty | 92.1(±3.7) | 93.8(±3.9) | 91.6(±8.7) | 89.0(±9.4) | NA | NA
[NAME] 3 [NAME] | US National | 93.2(±0.7) | 93.8(±0.8) | 93.2(±2.1) | 92.8(±2.0) | 93.4(±5.3) | 87.8(±6.6)
 | At or Above Poverty | 93.1(±0.9) | 93.7(±0.8) | 94.0(±2.1) | 92.2(±3.4) | 94.6(±4.3) | 86.0(±8.0)
 | Below Poverty | 93.2(±1.6) | 94.6(±2.0) | 92.5(±4.4) | 93.0(±2.3) | 91.3(±11.8) | 94.0(±7.6)
 | Unknown Poverty | 94.1(±2.9) | 93.9(±4.6) | 85.8(±11.6) | 96.7(±3.2) | NA | NA
[NAME] 1 Var¶¶ | US National | 94.9(±0.9) | 95.3(±0.8) | 94.3(±2.6) | 94.5(±2.5) | 95.7(±3.7) | 94.3(±6.7)
 | At or Above Poverty | 95.2(±1.0) | 95.5(±0.8) | 95.4(±2.5) | 94.0(±4.1) | 93.5(±5.9) | 94.0(±7.9)
 | Below Poverty | 94.7(±1.9) | 95.6(±2.1) | 92.8(±5.7) | 95.3(±2.7) | 99.2(±1.6) | 94.2(±10.1)
 | Unknown Poverty | 90.6(±6.3) | 87.6(±10.2) | 91.0(±11.2) | 92.7(±10.8) | NA | NA
[NAME]*** | US National | 78.5(±1.3) | 77.7(±1.5) | 77.9(±3.6) | 80.3(±3.5) | 78.7(±9.8) | 85.2(±8.1)
 | At or Above Poverty | 79.0(±1.5) | 78.5(±1.6) | 77.8(±4.4) | 80.7(±5.0) | 78.5(±10.9) | 84.8(±9.2)
 | Below Poverty | 77.3(±3.0) | 73.1(±4.5) | 77.6(±6.8) | 80.2(±5.1) | 78.6(±19.5) | 92.2(±10.5)
 | Unknown Poverty | 77.0(±8.2) | 74.1(±11.4) | 82.5(±14.7) | 78.1(±16.1) | NA | NA
[NAME] 1 Td or Tdap††† | US National | 89.1(±0.9) | 88.8(±1.0) | 87.4(±2.8) | 90.5(±2.2) | 87.2(±7.0) | 92.5(±3.1)
 | At or Above Poverty | 89.2(±1.0) | 89.0(±1.1) | 88.9(±2.9) | 90.3(±3.0) | 85.8(±10.3) | 93.0(±3.3)
 | Below Poverty | 88.6(±2.2) | 88.7(±2.6) | 84.8(±5.7) | 90.1(±3.6) | 88.8(±8.9) | 92.1(±8.2)
 | Unknown Poverty | 88.4(±4.8) | 83.3(±8.3) | 90.8(±8.5) | 95.3(±4.9) | NA | NA
[NAME] 1 Tdap§§§ | US National | 86.0(±0.9) | 85.9(±1.1) | 84.1(±3.0) | 87.1(±2.4) | 85.3(±7.2) | 89.7(±3.6)
 | At or Above Poverty | 86.4(±1.0) | 86.3(±1.2) | 84.7(±3.4) | 87.2(±3.3) | 84.1(±10.4) | 90.8(±3.7)
 | Below Poverty | 85.2(±2.3) | 84.9(±3.1) | 82.5(±5.9) | 86.6(±3.9) | 88.3(±8.9) | 85.7(±12.0)
 | Unknown Poverty | 84.3(±5.6) | 80.1(±8.5) | 90.8(±8.5) | 89.8(±9.6) | NA | NA
[NAME] 1 MenACWY¶¶¶ | US National | 77.8(±1.1) | 75.6(±1.3) | 77.0(±3.3) | 83.4(±2.8) | 71.7(±11.1) | 83.8(±7.1)
 | At or Above Poverty | 77.5(±1.2) | 76.2(±1.4) | 79.6(±3.8) | 80.0(±4.2) | 71.2(±12.0) | 86.1(±6.6)
 | Below Poverty | 78.4(±2.6) | 72.3(±4.1) | 72.4(±6.4) | 86.5(±3.8) | 72.9(±21.9) | 70.1(±28.1)
 | Unknown Poverty | 79.4(±6.4) | 71.3(±9.2) | 82.9(±13.2) | 90.0(±11.4) | NA | NA
FEMALE
[NAME] 1 HPV**** | US National | 57.3(±1.9) | 53.1(±2.3) | 55.8(±5.2) | 67.5(±5.0) | 73.3(±14.7) | 57.0(±11.4)
 | At or Above Poverty | 54.6(±2.2) | 53.4(±2.4) | 50.8(±6.6) | 60.4(±7.2) | 66.3(±21.2) | 56.7(±11.2)
 | Below Poverty | 66.8(±4.3) | 53.9(±6.8) | 64.0(±8.6) | 76.1(±7.0) | 82.7(±16.5) | NA
 | Unknown Poverty | 54.4(±12.0) | 43.0(±12.8) | NA | 70.7(±24.0) | NA | NA
[NAME] 2 HPV†††† | US National | 47.7(±2.0) | 44.0(±2.2) | 45.6(±5.2) | 57.7(±5.4) | 57.3(±15.2) | 47.2(±11.2)
 | At or Above Poverty | 45.3(±2.2) | 44.4(±2.4) | 39.9(±6.4) | 51.9(±7.4) | 59.3(±20.6) | 47.6(±11.4)
 | Below Poverty | 55.2(±4.6) | 42.8(±6.6) | 54.1(±8.9) | 64.8(±7.7) | 55.9(±23.4) | NA
 | Unknown Poverty | 48.2(±12.3) | 39.9(±12.6) | NA | 58.7(±30.3) | NA | NA
[NAME] 3 HPV§§§§ | US National | 37.6(±1.9) | 34.9(±2.1) | 34.2(±4.8) | 44.8(±5.6) | 43.2(±14.2) | 40.4(±11.0)
 | At or Above Poverty | 36.4(±2.1) | 35.0(±2.3) | 31.6(±6.0) | 42.2(±7.6) | 41.6(±18.6) | 42.8(±11.5)
 | Below Poverty | 41.5(±4.6) | 34.1(±6.2) | 39.0(±8.1) | 47.2(±8.6) | 46.2(±23.0) | NA
 | Unknown Poverty | 38.4(±12.8) | 34.7(±12.0) | NA | NA | NA | NA
HPV 3 dose series completion¶¶¶¶ | US National | 70.4(±2.5) | 71.8(±2.9) | 63.7(±7.3) | 69.5(±6.1) | 60.1(±16.9) | 77.2(±12.1)
 | At or Above Poverty | 71.9(±2.8) | 72.1(±3.2) | 65.1(±8.8) | 72.1(±8.0) | 65.1(±23.5) | 82.6(±12.5)
 | Below Poverty | 66.2(±5.7) | 66.8(±8.2) | 62.9(±12.0) | 66.2(±9.6) | 55.8(±26.0) | NA
 | Unknown Poverty | 72.2(±14.4) | 81.7(±13.4) | NA | NA | NA | NA
MALE
[NAME] 1 HPV**** | US National | 34.6(±1.9) | 26.7(±1.9) | 42.2(±5.5) | 49.6(±5.2) | 38.6(±14.0) | 26.3(±8.9)
 | At or Above Poverty | 30.8(±2.0) | 26.1(±2.0) | 41.3(±6.5) | 42.7(±7.5) | 39.0(±14.4) | 22.3(±9.9)
 | Below Poverty | 46.7(±4.5) | 30.9(±5.5) | 44.3(±10.5) | 59.1(±7.3) | NA | 48.4(±27.7)
 | Unknown Poverty | 32.8(±12.1) | 27.2(±11.6) | NA | NA | NA | NA
[NAME] 2 HPV†††† | US National | 23.5(±1.7) | 18.5(±1.7) | 27.5(±4.8) | 34.5(±5.3) | 24.8(±11.4) | 19.5(±8.0)
 | At or Above Poverty | 22.0(±1.9) | 18.4(±1.8) | 29.6(±6.3) | 32.7(±7.6) | 25.8(±12.4) | 15.3(±8.7)
 | Below Poverty | 28.7(±4.0) | 18.9(±4.3) | 24.6(±7.6) | 38.1(±7.5) | NA | NA
 | Unknown Poverty | 21.2(±11.6) | 20.2(±10.9) | NA | NA | NA | NA
[NAME] 3 HPV§§§§ | US National | 13.9(±1.4) | 11.1(±1.3) | 15.7(±3.8) | 20.3(±4.5) | NA | 9.1(±4.5)
 | At or Above Poverty | 13.0(±1.6) | 11.2(±1.5) | 16.0(±5.0) | 18.6(±6.4) | NA | 9.0(±5.3)
 | Below Poverty | 16.7(±3.0) | 11.4(±3.5) | 15.1(±6.1) | 22.3(±5.8) | NA | NA
 | Unknown Poverty | NA | NA | NA | NA | NA | NA
HPV 3 dose series completion¶¶¶¶ | US National | 48.3(±4.0) | 51.1(±4.7) | 44.8(±8.8) | 47.4(±9.0) | 48.4(±20.0) | 40.0(±18.8)
 | At or Above Poverty | 50.4(±4.8) | 52.8(±5.2) | 42.6(±11.3) | 50.9(±14.4) | 49.4(±25.2) | 45.7(±26.0)
 | Below Poverty | 44.3(±7.2) | 45.6(±11.8) | 47.7(±14.5) | 43.8(±11.1) | NA | NA
 | Unknown Poverty | NA | NA | NA | NA | NA | NA
 |  | *  Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588.
 |  | † Estimates with confidence intervals >20 may not be reliable.
 |  | § Adolescents in the 2013 NIS-Teen were born January 1995 through February 2001. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in the U.S. Virgin Islands (n=332) and Guam (n=363).
 |  | ¶ Poverty status was based on 2012 U.S. Census poverty thresholds (available at http://www.census.gov/hhes/www/poverty/data/threshld/index.html).
 |  | ** Reported by parent/guardian respondent.  Adolescents of Hispanic ethnicity may be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes.
 |  | ††  [NAME] 2 doses of measles-mumps-rubella (MMR) vaccine
 |  | §§    ≥3 doses of hepatitis B (Hep B) vaccine.
 |  | ¶¶    [NAME] 1 dose of varicella (Var) vaccine among adolescents without a history of varicella disease.
 |  | ***   [NAME] 2 doses of varicella (Var) vaccine among adolescents without a history of varicella disease.
 |  | [NAME] 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since age 10 years.
 |  | §§§ ≥ 1 dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since age 10 years.
 |  | ¶¶¶   ≥1  dose of meningococcal conjugate vaccine or meningococcal -unknown type (MenACWY) vaccine.
 |  | ****   ≥1 dose of human papillomavirus (HPV) vaccine, either quadrivalent or bivalent. Percentages reported among females only (N=8,710) and among males only (N=9,554)
 |  | †††† ≥2 doses of human papillomavirus (HPV) vaccine, either quadrivalent or bivalent.
 |  | §§§§ ≥3 doses of human papillomavirus (HPV) vaccine, either quadrivalent or bivalent. Some adolescents may have received more than the three recommended HPV doses.
 |  | ¶¶¶¶  Percent of females or males who received three doses among those who had at least one human papillomavirus (HPV) vaccine dose with at least 24 weeks between the first dose and the interview date.